# reload+after+2024-01-20 02:48:04.254081
address1§111 West Lemon Avenue
city§Monrovia
state§CA
zip§91016
country§United States
phone§626 305 5900
website§https://www.xencor.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
fullTimeEmployees§281
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Bassil I. Dahiyat Ph.D.', 'age': 53, 'title': 'Co-Founder, CEO, President & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1079247, 'exercisedValue': 0, 'unexercisedValue': 5806690}, {'maxAge': 1, 'name': 'Mr. John J. Kuch', 'age': 64, 'title': 'Senior VP & CFO', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 660747, 'exercisedValue': 0, 'unexercisedValue': 2069137}, {'maxAge': 1, 'name': 'Dr. John R. Desjarlais Ph.D.', 'age': 59, 'title': 'Executive VP of Research & Chief Scientific Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 711447, 'exercisedValue': 0, 'unexercisedValue': 4497949}, {'maxAge': 1, 'name': 'Ms. Celia E. Eckert J.D.', 'age': 50, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 646247, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nancy  Valente M.D.', 'age': 64, 'title': 'Executive VP & Chief Development Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 28160, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles  Liles', 'title': 'Associate Director and Head of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jennifer  Sandoz', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeremy  Grunstein Ph.D.', 'title': 'Senior Vice President of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kirk  Rosemark RAC', 'age': 58, 'title': 'Senior Vice President of Regulatory Affairs & Quality Assurance', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric P. Kowack', 'title': 'Senior Vice President of Program Leadership & Alliance Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§7
compensationRisk§7
shareHolderRightsRisk§4
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.682
priceToSalesTrailing12Months§8.628865
currency§USD
dateShortInterest§1702598400
forwardEps§-3.78
exchange§NGM
quoteType§EQUITY
shortName§Xencor, Inc.
longName§Xencor, Inc.
firstTradeDateEpochUtc§1386081000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§26aa4068-c78f-37c3-ba4d-6b3d2f7ac6ec
gmtOffSetMilliseconds§-18000000
targetHighPrice§59.0
targetLowPrice§22.0
targetMeanPrice§39.83
targetMedianPrice§37.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§12
quickRatio§10.361
grossMargins§-0.65794
ebitdaMargins§-0.92445
trailingPegRatio§None
